ARTICLE | Financial News

SQZ raises $72M series C

August 8, 2018 12:33 PM UTC

Cell therapy company SQZ Biotechnologies Co. (Watertown, Mass.) raised $72 million in an oversubscribed, untranched series C round. New investors Everblue, Illumina Ventures, Invus, Orient Life and Viva Ventures Biotech Group participated, as did existing investors Bridger Healthcare Partners, Quark Ventures' Global Health Science Fund, GV, The JDRF T1D Fund, NanoDimension and Polaris.

SQZ is developing antigen presenting cell (APC) therapies for cancer indications to deliver tumor-associated antigens that prime and activate a patient’s endogenous killer T cells against a target of choice. The company's platform engineers cells by injecting bioactive materials, including proteins and peptides, directly into the cytosol without affecting cell health (see "SQZ Biotech's Main Squeeze")...

BCIQ Company Profiles

SQZ Biotechnologies Co.